Chrissy Teigen, Fertility, and What Public Disclosure Actually Means for Your IVF Journey

Why Chrissy Teigen's Fertility Story Matters Clinically

Chrissy Teigen is not a clinician, but her public accounts of IVF cycles, embryo selection, pregnancy loss, and postpartum grief have done something clinical education often fails to do: they made the biological reality of assisted reproduction visible to a mainstream audience. She described ovarian stimulation, discussed the emotional weight of embryo grading, and in 2020 shared photographs from the hospital room where she lost a pregnancy at 20 weeks, naming the baby Jack.

That level of candor is rare, and it carries weight. Research published in the journal Human Reproduction found that women who felt socially isolated during IVF reported significantly worse psychological outcomes, a finding that speaks directly to why public narratives about fertility treatment matter. When someone with Teigen's reach says "I did IVF, and it was hard, and loss happens," the isolation that characterizes so many women's fertility experiences is, at least partially, disrupted.

This article uses her story as a clinical and legal lens, not a gossip frame. You deserve a clear account of what IVF actually involves biologically, what the law says about your right to privacy around fertility treatment, and where the science stands on the procedures she described.

What She Actually Said: A Factual Timeline

Teigen has discussed fertility treatment across multiple interviews and social media posts spanning more than a decade. Key documented disclosures include:

• Egg retrieval and IVF to conceive her first child, Luna (born 2016), after acknowledging years of trying to conceive without success
• Multiple embryo transfers and embryo selection discussions
• The October 2020 pregnancy loss of a baby she and John Legend named Jack, described publicly as a partial placental abruption
• A 2023 pregnancy she described as achieved via a "surrogate embryo" transfer, which she later clarified was a gestational surrogacy arrangement

Each of these represents a voluntary disclosure. None of it was legally required.

The Legal Reality: What Fertility Patients Must and Must Not Disclose

You are not Chrissy Teigen. You have no audience, no publicist, and no reason to share your fertility treatment with anyone unless you choose to. The legal framework in the United States is actually quite protective of your privacy around reproductive care.

HIPAA and Your Fertility Records

The Health Insurance Portability and Accountability Act covers your medical records, including those generated during fertility treatment. Under HIPAA, your reproductive health records cannot be shared with employers, family members, or third parties without your written authorization. Fertility clinics are covered entities under HIPAA, which means your ovarian reserve testing results, embryo reports, cycle outcomes, and transfer records are protected.

The 2024 final rule issued by the Department of Health and Human Services added specific language strengthening privacy protections for reproductive health care, directly in response to the post-Dobbs legal environment. This matters: if you live in a state where certain reproductive procedures are legally contested, your fertility records cannot generally be disclosed to law enforcement without a court order and, in many circumstances, not even then under the new rule.

Employer Disclosure: What You Actually Owe Your Boss

Nothing. You owe your employer nothing about your IVF cycle.

You may need to request time off for egg retrieval (typically an outpatient procedure requiring one day of recovery), monitoring appointments (often early-morning blood draws and ultrasounds every two to three days during stimulation), and embryo transfer (a brief procedure, usually without sedation, followed by a day of rest). The Family and Medical Leave Act may apply if your fertility treatment is connected to a diagnosed medical condition such as PCOS, premature ovarian insufficiency, or endometriosis, but you are not required to name the specific procedures. "Medical appointments" is legally sufficient language in most FMLA-covered situations.

Insurance Disclosure and Fertility Coverage

This is where disclosure gets more complicated. If you are using insurance to cover IVF, you will likely need a diagnosis code on your claim. Infertility is coded under ICD-10 as N97 (female infertility) with various subcategories, and your insurer will see that diagnostic category. Fifteen U.S. States currently mandate some level of infertility coverage, though the scope varies widely. In states without a mandate, coverage is discretionary.

What your insurer cannot do, under the ACA, is use a pre-existing condition related to infertility to deny you coverage or raise your premiums. That protection holds regardless of what diagnosis appears on your fertility claim.

IVF Protocols: The Biology Teigen Described, Explained for Women at Every Life Stage

Teigen's descriptions of stimulation, egg retrieval, and embryo transfer are clinically accurate in their broad strokes. Here is what each stage actually involves, and how it differs depending on where you are in your reproductive life.

Ovarian Stimulation: What Happens in Your Body

IVF begins with controlled ovarian hyperstimulation. You inject gonadotropins (typically follicle-stimulating hormone alone or combined with luteinizing hormone) for approximately 8 to 14 days to recruit multiple follicles simultaneously. ASRM guidelines recommend individualized stimulation protocols based on ovarian reserve markers including antral follicle count and anti-Mullerian hormone (AMH) levels.

Your response to stimulation is directly tied to your hormonal status:

• Reproductive years (roughly 18 to 37): AMH levels above 1.0 ng/mL generally predict adequate response. Protocols are titrated to avoid ovarian hyperstimulation syndrome (OHSS), which is more common in women with PCOS and can be serious.
• Ages 38 to 42: Ovarian reserve declines. Lower AMH and antral follicle counts mean stimulation may retrieve fewer eggs per cycle, and embryo quality declines with oocyte age. CDC ART surveillance data show live birth rates per egg retrieval cycle fall from approximately 40% in women under 35 to roughly 17% in women ages 38 to 40.
• Ages 43 and older: Success rates drop significantly. For women over 42 using their own eggs, the CDC reports approximately 5 to 7% live birth rates per cycle. Many women in this group choose donor eggs, which restore success rates to those of the donor's age.
• Perimenopause: Defined by irregular cycles and rising FSH, perimenopause significantly complicates stimulation. AMH may be very low or undetectable. IVF is still possible but often requires higher gonadotropin doses with fewer retrieved oocytes.

Egg Retrieval and Embryo Development

Egg retrieval is transvaginal and ultrasound-guided, performed under sedation in most U.S. Clinics. The procedure takes approximately 20 to 30 minutes. Retrieved oocytes are fertilized the same day, either by conventional insemination or intracytoplasmic sperm injection (ICSI).

Embryos are cultured for three to five days (cleavage stage) or five to six days (blastocyst stage). ASRM recommends blastocyst culture when multiple embryos are available, as blastocyst transfer is associated with higher implantation rates than cleavage-stage transfer.

Embryo Transfer: Fresh vs. Frozen

Teigen has discussed both fresh and frozen embryo transfers in interviews. The distinction is clinically meaningful.

A fresh transfer occurs within the same stimulation cycle. Estrogen and progesterone levels are artificially elevated from stimulation, which may impair endometrial receptivity in some women. A frozen embryo transfer (FET) uses a cryopreserved embryo in a subsequent cycle, allowing the uterine lining to be prepared under more controlled hormonal conditions. A 2019 trial published in the New England Journal of Medicine (the Soft trial, N=782) found no significant difference in live birth rates between fresh and frozen transfers in women without PCOS, but a companion trial in women with PCOS did favor frozen transfer.

Progesterone supplementation is required for frozen transfers and continues through the first trimester if pregnancy occurs. Most clinics use intramuscular progesterone-in-oil or vaginal progesterone suppositories; the choice affects patient experience substantially.

Preimplantation Genetic Testing

Teigen has referenced embryo selection in interviews, which often refers to preimplantation genetic testing for aneuploidies (PGT-A). This biopsy of the trophectoderm at the blastocyst stage screens for chromosomal abnormalities. ASRM's 2023 committee opinion on PGT-A states that it may improve implantation rates per transfer in some patient populations but does not consistently improve cumulative live birth rates across all age groups, particularly in women under 38 with normal embryo morphology.

Pregnancy Loss After IVF: The Biology of Jack

Teigen described the loss of her pregnancy at 20 weeks in 2020 as involving a partial placental abruption, hemorrhage, and multiple blood transfusions. This was not a miscarriage in the first-trimester sense. It was a second-trimester pregnancy loss, a category that is biologically and clinically distinct and that carries its own grief weight.

Pregnancy loss before 20 weeks affects approximately 10 to 20% of recognized pregnancies, per ACOG. Loss between 20 and 27 weeks, sometimes called late miscarriage or second-trimester loss, is less common but devastatingly new. Placental abruption, premature labor, and fetal anomalies incompatible with life account for many of these cases.

The clinical protocol after second-trimester loss includes:

• Delivery, most often induced, with full obstetric and labor-and-delivery support
• Pathological examination of the placenta and, if parents consent, the fetus
• Grief counseling referral
• Investigation for underlying conditions (clotting disorders, uterine anomalies, chromosomal issues in the embryo)
• A waiting period of generally one to three menstrual cycles before subsequent transfer, though data on optimal timing is limited

What Teigen did by photographing and naming Jack was clinically significant beyond its emotional resonance. Research in BMJ Open found that women who experienced perinatal loss reported higher satisfaction with care when staff acknowledged the baby as a person, offered mementos, and supported the family's own meaning-making. She normalized that acknowledgment for millions of women who had been told, explicitly or implicitly, to "move on."

Gestational Surrogacy: What Teigen's 2023 Pregnancy Actually Involved

Teigen announced in 2023 that she had a baby via gestational surrogacy, using an embryo created from her own egg and Legend's sperm carried by a gestational carrier. This is a legally and medically distinct path from traditional surrogacy.

Medical Process for the Genetic Mother

As the genetic and intended mother in a gestational surrogacy arrangement, Teigen would have undergone IVF egg retrieval, embryo creation, and embryo cryopreservation. The embryo transfer itself was performed in the gestational carrier.

The intended mother in this arrangement takes no fertility medications at the transfer stage. The carrier undergoes uterine preparation with estradiol and progesterone. Legal agreements governing embryo ownership, parental rights, and compensation must be executed before any medical procedures in the carrier, per ASRM guidelines on third-party reproduction.

What You Need to Know If You Are Considering Surrogacy

Gestational surrogacy is legal in most U.S. States but explicitly illegal or legally risky in a handful. The legal field changed after Dobbs and varies by state. You need a reproductive attorney before a fertility clinic can ethically proceed with a carrier cycle. Costs typically range from $100,000 to $200,000 all-in when legal, agency, carrier compensation, and medical fees are included.

What Women Are Never Required to Disclose: A Practical Privacy Framework

This framework covers the four most common situations where women feel pressured to disclose fertility treatment.

| Situation | What you are required to disclose | What you can legally withhold | |---|---|---| | Employer asking about absences | A need for medical leave (not the diagnosis) | Your specific procedure, clinic, diagnosis, or outcome | | Family members asking why you are not pregnant yet | Nothing | Everything. "We're working on it" is a complete answer | | Insurer processing your claim | ICD-10 diagnosis code (handled by your clinic) | Specific cycle outcomes, embryo count, or transfer details | | New OB-GYN after conception via IVF | Yes, disclose IVF conception; it affects prenatal care protocols | Which clinic, how many failed cycles, embryo grading details |

The only clinical disclosure that is both obligatory and protective is telling your obstetric provider that your pregnancy was achieved through IVF. IVF pregnancies carry a modestly elevated risk of placenta previa, placental abruption, low birth weight, and preterm birth compared to spontaneous conception, independent of maternal age or multiple gestation. Your provider needs this information to calibrate your prenatal monitoring.

Who IVF Is and Is Not Right For, by Life Stage

Women in Reproductive Years With a Diagnosed Condition

If you have PCOS, premature ovarian insufficiency, tubal factor infertility, endometriosis causing tubal damage, or unexplained infertility after 12 months of timed intercourse (or 6 months if you are over 35), IVF is a well-supported first- or second-line intervention. ACOG recommends referral to a reproductive endocrinologist after 12 months of infertility in women under 35, and after 6 months in women ages 35 to 40.

Women Ages 38 to 42

IVF is appropriate and widely used, but the conversation must include honest probability data. The Society for Assisted Reproductive Technology (SART) 2020 data show that women ages 38 to 40 have approximately a 26% live birth rate per intended egg retrieval, dropping to around 13% for ages 41 to 42. Donor egg discussion is appropriate, not dismissive.

Women Over 43

Own-egg IVF has a low probability of success. Donor eggs from a younger donor restore success rates substantially. This is a medically sound option; the child is genetically the partner's and gestated by you, with all the biological bonding of pregnancy.

Women in Perimenopause

IVF is possible but technically difficult. Perimenopausal women have highly variable hormonal environments, and stimulation protocols require careful individualization. If you are perimenopausal and want to attempt IVF, a reproductive endocrinologist with experience in diminished ovarian reserve is non-negotiable.

Women for Whom IVF May Not Be Appropriate

IVF is not indicated as a first step in women under 35 with no diagnosed cause of infertility who have been trying for less than 12 months. Medically, you may simply need more time. Less intensive interventions like ovulation induction with clomiphene or letrozole, or intrauterine insemination, may be tried first depending on your clinical picture.

The Evidence Gap: What We Still Do Not Know

Women have been historically underrepresented in reproductive research, which is an irony given that reproductive medicine is almost entirely about female biology. Specific gaps relevant to this topic include:

• Long-term health outcomes of multiple IVF cycles in women are not well characterized. A 2019 Danish cohort study (n=25,874) found no increased cancer risk overall after ovarian stimulation, but follow-up beyond 15 years is limited.
• Psychological outcomes after perinatal loss in IVF-conceived pregnancies are understudied relative to spontaneous conception loss, even though the grief burden may be compounded by the investment, financial and otherwise, of IVF.
• Optimal protocols for women with PCOS undergoing frozen embryo transfer remain debated. Most major trials, including SOFT, excluded women with PCOS from their primary analyses.
• Data on IVF in gender-diverse patients assigned female at birth are sparse, and this population is systematically excluded from most large registry analyses.

When your clinician cites success rate data, ask which population it comes from and whether it includes your specific age, diagnosis, and embryo type. Aggregate statistics and your individual prognosis are different numbers.

Talking to Your Fertility Clinic: Questions Teigen's Story Prompts You to Ask

Teigen's candor surfaced clinical questions that patients often do not know to ask. Bring these to your reproductive endocrinologist:

1. What is my specific AMH and antral follicle count, and what do those numbers predict for my response to stimulation?
2. Are you recommending fresh or frozen transfer for me, and why?
3. What is the probability of live birth per retrieval cycle and per transfer cycle for someone with my profile specifically, not population averages?
4. If I do PGT-A, how will it affect my cumulative live birth rate rather than just my per-transfer rate?
5. What is your clinic's protocol if I experience pregnancy loss after transfer?
6. If I am considering stopping after a certain number of cycles, at what point would you recommend discussing donor eggs or other paths?

These questions are not aggressive. They are the questions any woman receiving competent reproductive care deserves to have answered with specific data.